All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Bimekizumab maintenance therapy for patients with moderate-to-severe plaque psoriasis: 4-year results from BE BRIGHT
|
An analysis of data pooled from the 52-week phase III BE VIVID trial (NCT03370133), the 56-week phase III BE SURE (NCT03412747) and BE READY (NCT03410992) trials, and their OLE BE BRIGHT (NCT03598790) assessed the maintenance of response in 771 patients with moderate-to-severe plaque psoriasis treated with bimekizumab through 4 years.1 Patients received bimekizumab 320 mg Q4W until Week 16, then either Q4W or Q8W until OLE entry and during the OLE. Results from this analysis were presented at the EADV Congress 2024 by Gordon.1 |
| Key learnings |
| At Year 1, 90.7% of patients had a PASI 90 response; 96.5%, 93.7%, and 87.9% of patients maintained their responses at Years 2, 3, and 4, respectively. |
| At Year 1, 75.6% of patients were PASI 100 responders; at Years 2, 3, and 4, 87.3%, 80.9%, and 74.3% of patients, respectively, continued to respond. |
| An IGA 0/1 response was achieved by 88.8% of patients at Year 1, and 96.4%, 93.3%, and 89.5% of patients maintained their responses at Years 2, 3, and 4, respectively. |
| At Year 1, 80.5% of patients were DLQI 0/1 responders, and the responses were maintained by 92.4%, 88.3%, and 82.9% of patients at Years 2, 3, and 4, respectively. |
| These findings demonstrate the benefit of bimekizumab maintenance therapy in patients who responded to treatment after 1 year, with a high proportion of patients maintaining these responses through 4 years. |
Abbreviations: DLQI, Dermatology Life Quality Index; EADV, European Academy of Dermatology and Venereology; IGA, Investigators Global Assessment; OLE, open-label extension; PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks.
- Gordon KB. Bimekizumab maintenance of response from the end of pivotal trials through 4 years: Results in patients with moderate to severe plaque psoriasis from BE BRIGHT. Poster Abstract #P3085. Presented at: European Academy of Dermatology and Venereology Congress; Sep 25–28, 2024; Amsterdam, NL.
Your opinion matters
6 votes - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox